Bacteria as the cause of ulcerative colitis

Gut

Volumn 48, Issue 1, 2001, Pages 132-135

  Campieri, M ^a   Gionchetti, P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MESALAZINE; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; COLON FLORA; ESCHERICHIA COLI; HUMAN; IMMUNOLOGICAL TOLERANCE; LACTOBACILLUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLITIS, ULCERATIVE; COLON; ESCHERICHIA COLI INFECTIONS; HUMANS; INTESTINAL MUCOSA; MODELS, ANIMAL; PROBIOTICS; T-LYMPHOCYTES;

EID: 0035173609     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.1.132     Document Type: Review

References (70)

1. On simple ulcerative colitis and other intestinal ulcers
2. Helicobacter pylori: From art to science
3. Salazopyridin, a new sulfanilamide preparation
4. An experiment to determine the active therapeutic moity of sulphasalazine
5. Sulfasalazine revisted: A meta-analysis of 5-aminosalylic acid in the treatment of ulcerative colitis
6. Intravenous regimen for severe attacks of ulcerative colitis
7. Mycobacterium paratuberculosis found in Crohn's disease DNA in Crohn's disease tissue
8. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease
9. Microbial factors in chronic intestinal inflammation
10. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: Sticking the pieces together with sugar
11. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis
12. Diarrheagenic Escherichia coli
13. Absence of Escherichia coli, Listeria moncytogenes, and Klebsiella pneumonae antigens within inflammatory bowel disease tissues
14. Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease
15. Ulcerative colitis and Escherichia coli with adhesive properties
16. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea
17. Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls
18. Verocytoxin-Producing Escherichia coli O2:H5 isolated from patients with ulcerative colitis
19. The intestinal mucus layer from patients with inflammatory bowel disease harbours numbers of bacteria compared with controls
20. Short chain fatty acids in the human colon
21. The colonic epithelium in ulcerative colitis: An energy deficient disease?
22. Incidence and activities of sulphate-reducing bacteria in patients with ulcerative colitis
23. Hydrogen sulphide: A bacterial toxin in ulcerative colitis?
24. Ulcerative colitis in laboratory animals induced by pepsin inhibitors
25. Salicylates inhibit bacterial sulphide production within the colonic lumen in ulcerative colitis
26. Comparison of bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis
27. Varying caecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats
28. Induction and prevention of colonic inflammation in IL-2-deficient mice
29. Interleukin-10-deficient mice develop chronic enterocolitis
30. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis
31. Controlled trial of intravenous metronidazole as adjunct to corticoids in severe ulcerative colitis
32. The efficacy of tobramycin in the treatment of ulcerative colitis
33. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis
34. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double blind, placebo-controlled trial
35. A prospective randomised controlled trial of oral ciprofloxacin in acute ulcerative colitis
36. Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study
37. Ciprofloxacin as a treatment for ulcerative colitis - Not yet
38. Intestinal flora in health and disease
39. Mucosal tolerance
40. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease
41. Oral tolerance in disease
42. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis
43. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes
44. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
45. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice
46. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)
47. T cell specificity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans
48. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria
49. Permeability in Crohn's disease: Altered barrier function in healthy relatives?
50. Genetics of inflammatory bowel disease
51. State of the art concerning probiotic strains in milk products
52. The coming age of probiotics
53. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?
54. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat
55. Mucosally associated bacterial flora of the human colon: Quantitative and species differences between normal and intestinal colonic biopsies
56. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG
57. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fibre on acid-induced colitis in rat
58. The effect of Lactobacillus strains and oat fibre on methotrexate-induced enterocolitis in rats
59. Lactobacillus species prevents colitis in interleukin-10 gene-deficient mice
60. Continuous feeding of Lactobacillus plantarum attenuates established colitis in interleukin-10 deficient mice
61. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
62. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
63. Über die Grundlagen einer neuen ursächlichen Bekämpfung der pathologischen Darmflora
64. Manipulation of intestinal microflora
65. Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalicylic acid (5-ASA)
66. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled
67. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial
68. Effect of probiotic therapy on pro- and anti-inflammatory cytokins in pouchitis
69. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression